

Institutional Biosafety Committee Meeting

9/8/25

1:30-3:00pm

Zoom Virtual Meeting

Institutional Biosafety Committee Meeting minutes

Meeting Attendance:

- Members in attendance:
 - Elena Demireva
 - Jamie Willard-Smith
 - Carrie Anglewicz
 - Jonathan Hardy
 - Dave Morgan
 - Guo-Qing Song
 - Michael Bachmann
 - Sarah Roosa
 - Andras Komaromy
 - Jan Patterson Samson
- Members not in attendance:
 - Raj Kulkarni
 - Carolina de Aguiar Ferreira
 - Simon Petersen-Jones
- Others in attendance:
 - Chris Colvin
 - Alessandra Hunt
 - Luis Ochoa Carrera

Call to order:

Elena Demireva

Roll call:

Chris Colvin

Discussion of the agenda:

- Approved as written.

Discussion of minutes:

- Approved as written.

Institutional Biosafety Committee Meeting

9/8/25

1:30-3:00pm

Zoom Virtual Meeting

Registration review:

Study Info

Safety0001205: [REDACTED]

Gynecologic cancer

Training: Complete for all members listed

NIH III D-4, RG-2, BSL-2

This registration has been approved with edits. The PI has been asked to clarify the following:

- Basic Summary
 - 3: Provide more information on the genes that will be used, viral vector and animal model work.
- Biosafety Summary
 - 2: Add lenti vector. State that vectors are not being made in-house and are being purchased.
- Virus
 - 1: Update to include generation of Lentiviral vector.
- rDNA Usage
 - 3b: Include species and bioactivity for all inserts.
 - 10: Add “in case of loss or theft EHS and MSU police will be contacted.”
- rDNA Work Description
 - 4: Yes, if lenti is this VSV pseudotyped?
 - 5: Provide details on the pathogenicity, host range or generation
 - 6: Provide genus, species, and strain of vector
- Risk Group
 - 2: If using a 2nd generation Lentiviral vector this falls under BSL-2+.

Study Info

Safety0001285: [REDACTED]

GML_Safety_2025

Training: Complete for all members listed

NIH III D-4b, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- Biosafety Summary
 - 2: Mention use of transposases.
- Tissues
 - 3e: Add all cells to the Flow core addendum, e.g. include immune cells or others that will be sorted.
- rDNA usage
 - 3b: Add species and bioactivity of all inserts.

Institutional Biosafety Committee Meeting

9/8/25

1:30-3:00pm

Zoom Virtual Meeting

- Genetically Modified Animals and Invertebrates
 - Include use of transposases.

Study Info

Safety0001291: [REDACTED]

[REDACTED] - Lipid Binding and Localization of Plastoglobule Proteins

Training: Complete for all members listed

NIH III E-2-a, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- rDNA Usage
 - 5a: Remove plant species that are recipients.
- rDNA Work Description
 - 2: Remove E. coli from recipients.

Study Info

Safety0001315: [REDACTED]

AAV vectors 32

Training: Complete for all members listed

NIH III D-4, RG-1, BSL-2

This registration has been approved with edits. The PI has been asked to clarify the following:

- Basic Summary
 - 3: Typo on “astrocytes”. Last sentence cells should be Aspc-1.
- Biosafety Summary
 - 2: Where will the cell line work be done?
 - 2: Include rationale why are you using the Aspc-1 cells when looking at Astrocytes.
- Primary Cells or Cell Lines
 - 1: Update Aspc-1 cells to BSL-2 as they are of human origin.
- Risk Group
 - Update to RG-2 and BSL-2 because of Aspc-1 cells
- rDNA Usage
 - 4e. Address any features that improve safety of vector
- rDNA Work Description
 - 5. Provide details on the pathogenicity, host range or generation system
- Exposure Assessment
 - 1: Address the possibility of exposure to Bloodborne pathogens with the use of human cell lines.

Institutional Biosafety Committee Meeting

9/8/25

1:30-3:00pm

Zoom Virtual Meeting

- 1: Remove statement “They have an exceedingly small risk of cancer to animals and humans who come in direct unshielded contact with the material.”.
- 3: BSC: Do you have one in your lab for use with the human cells? Where will that work be done?

Study Info

Safety0001319: [REDACTED]

Acyltransferase enzymes expressed from Escherichia coli

Training: Complete for all members listed

NIH III E-1, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- Biosafety Summary
 - Reduce/Summarize information provided.
- Bacteria
 - Include both BL21(DE3) and the K12 strains in the table
- Exposure Assessment
 - 3: Update eye wash test date

Study Info

Safety0001324: [REDACTED]

[REDACTED] Lab Biosafety

Training: Complete for all members listed

NIH III D-E-2-b-(4), RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- rDNA Usage
 - 3b: Add species and bioactivity for all inserts.
 - 4a: Comment on the large list of vectors needed or attach a supporting document
 - 4e: Change to N/A
 - 5a: Remove Chlamydomonas as it is a recipient.
- rDNA Work Description
 - 2: Remove E.coli from the recipient list.

Study Info

Safety0001325: [REDACTED]

[REDACTED] Wolbachia based Vector-borne disease control-2025

Training: Complete for all members listed

Institutional Biosafety Committee Meeting

9/8/25

1:30-3:00pm

Zoom Virtual Meeting

NIH III D, RG-2, BSL-2, ACL-2

This registration has been approved with edits. The PI has been asked to clarify the following:

- Basic Summary
 - 3: Typo “CRISP”
- Biosafety Summary
 - 2: Typo “insert”. Will you still use Zika or other viruses in this work? Include information if ZKV work is ongoing.
- Virus
 - 1: Add Zika and other viruses in use.
- rDNA Work Description
 - 5: Include Zika information.
- Exposure Assessment
 - 1: Include risks of working with Zika and Malaria.
 - 1: Remove 2nd paragraph statement starting with “We have a lot of methods to avoid the exposure risk to viral work and biting insects in our lab....”
 - 3: Include Centrifuge with aerosol containment.

Study Info

Safety0001328: [REDACTED]

[REDACTED]_Carbon Flux 2

Training: Complete for all members listed

NIH III E-2, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- Biosafety Summary
 - 2: Include all plant species that you are working on with this project.
- rDNA Usage
 - 5a: Remove plant recipients.
- rDNA Work Description
 - 2: Include all 6 plant species. Missing Glycine Max, Hordeum vulgare and Triticum aestivum.
- Exposure Assessment
 - 1: Expand on “no harm” based on genes expressed if these plants are released since some of them are food crops.

Study Info

Safety0001329: [REDACTED]

[REDACTED]-EE-lipase

Training: Complete for all members listed

NIH III D-6, RG-1, BSL-1

Institutional Biosafety Committee Meeting

9/8/25

1:30-3:00pm

Zoom Virtual Meeting

This registration has been approved with edits. The PI has been asked to clarify the following:

- rDNA Usage
 - 3c: Leave only biosafety hazards and remove chemical hazards. Removed statement starting with “All risks can be mitigated.....”
- Exposure Assessment
 - 1: Remove information, provide information on consequences of exposure to the bacteria in terms of biosafety.

Study Info

Safety0001334: [REDACTED]

[REDACTED]-Spatial regulation and specificity of RNA modification enzymes

Training: Complete for all members listed

NIH III D-2, RG-2, BSL-2

This registration has been approved with edits. The PI has been asked to clarify the following:

- Basic Information
 - 3: Include information on what RNA erasers are and how they work.
- Biosafety Summary
 - 3: Define FTO acronym.
- rDNA Usage
 - 2: Remove selections for NIH III-E and III-F categories, leave only III-D categories.
- rDNA Work Description
 - 1: Add links or references for purchased materials.
 - 2: Remove E. coli from recipients list.
- Risk Group and Containment Practices
 - Why is BSL2+ needed?
- Exposure Assessment
 - 3: Include Centrifuge with aerosol containment.
 - 5: Update to 10% bleach for 10 min contact time and 70% EtOH for 5 min contact time.
- Supporting Documents
 - Need both sharps forms if using with human or infectious materials.

Study Info

Safety0001338: [REDACTED]

Isopod

Training: Complete for all members listed

NIH III D-6, RG-1, BSL-1

Institutional Biosafety Committee Meeting

9/8/25

1:30-3:00pm

Zoom Virtual Meeting

This registration has been approved with edits to be reviewed by Ad-Hoc committee (Jamie Willard, Michael Bachmann, and David Morgan). The PI has been asked to clarify the following:

- Basic Information
 - 3: Typo “ by product”.
- Exposure assessment
 - 5: Define detergent to be used.
- Waste Management
 - 1: If only using soap, water and air for decontamination we will need a confirmation of kill with the stated method. This can be added to the supporting documents page.

New Items:

- N/A

Previous Submissions:

- Safety0001223 [REDACTED]
- Safety0001206 [REDACTED]
- Safety0001245 [REDACTED]
- Safety0001010 [REDACTED]
- Safety0001309 [REDACTED]

Next Meeting:

October 7, 2025 1:30 pm via zoom